Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE

Add to watchlist

$4.4

-2.65

-37.68%

Market closed

Open in about 7 hours

+63.43%

month

+63.43%

quarter

+22.57%

year

Market Cap	427.59M
Enterprise value	389.59M

P/E	-3.65
EV/Sales	N/A
EV/EBITDA	-3.85
Price/Sales	N/A
Price/Book	1.46
PEG ratio	-0.16
EPS	-2.51

Revenue	N/A
EBITDA	-138.79M
Income	-135.28M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Profit margin
Jun 2023	0	-35.17M
Sep 2023	0	-34.88M
Dec 2023	8.75M	-33.25M	-379.94%
Mar 2024	1.06M	-31.96M	-3004.51%

Monte Rosa Therapeutics Financials Estimate

Q Y

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Analyst Estimates
Mar 2024	1.06M	-31.96M	-3004.51%
Sep 2025	2.2M	-34.34M	-1561.24%
Oct 2025	2.72M	-29.12M	-1070.23%
Dec 2025	6.14M	-28.23M	-459.26%

Analysts Price target
Financials & Ratios estimates

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Earnings per share (EPS)
2023-11-09	-0.75	-0.7
2024-03-14	-0.57	-0.58
2024-05-09	-0.56	-0.53

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Debt to assets
Jun 2023	278616000	64.96M	23.32%
Sep 2023	252103000	67.57M	26.81%
Dec 2023	303755000	124.50M	40.99%
Mar 2024	266745999	114.22M	42.82%

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Cash Flow
Jun 2023	-25.32M	18.55M	1.2M
Sep 2023	-24.70M	35.62M	1.10M
Dec 2023	29.63M	14.29M	25.17M
Mar 2024	-38.16M	9.85M	246K

Monte Rosa Therapeutics alternative data

Monte Rosa Therapeutics
Employees

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Employee count
Aug 2023	133
Sep 2023	133
Oct 2023	133
Nov 2023	133
Dec 2023	133
Jan 2024	133
Feb 2024	133
Mar 2024	133
Apr 2024	133
May 2024	133
Jun 2024	130
Jul 2024	130

Monte Rosa Therapeutics
Hedge Funds Holdings Q1 2023

30.06% -58.37%

of GLUE is owned by hedge funds

36 -30

hedge funds hold GLUE stock

14.19M -27.12M

shares is hold by hedge funds

GLUE hedge funds holdings changes

Monte Rosa Therapeutics
Insider Trading

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE): Insider trades (number of shares)
Period	Buy	Sel
Jun 2024	0	1207
Jul 2024	0	1610
Sep 2024	0	1699779
Oct 2024	0	157895

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	29 Oct 2024	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	52,305	$9.08	$475,034
Sale	29 Oct 2024	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	15,600	$9.41	$146,796
Sale	28 Oct 2024	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	89,990	$9.66	$869,213
Sale	20 Sep 2024	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	1,132,566	$6.53	$7,395,656
Sale	13 Sep 2024	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	9,269	$6.16	$57,097
Sale	12 Sep 2024	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	16,047	$6	$96,314
Sale	11 Sep 2024	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	541,897	$6	$3,251,382
Sale	5 Jul 2024	DUNN EDMUND officer: Principal Accounting Officer officer: Principal Accounting O..	Common Stock	1,610	$3.83	$6,166
Sale	3 Jun 2024	DUNN EDMUND officer: Principal Accounting Officer officer: Principal Accounting O..	Common Stock	1,207	$4.04	$4,876
Purchase	28 Jun 2021	WALKER PAUL EDWARD 10 percent owner	Common Stock	1,050,000	$19	$19,950,000

GLUE insider trading transactions

Monte Rosa Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Markus Warmuth M.D. (1971) Pres, Chief Executive Officer & Director	54		$899,170
Mr. Ajim A. Tamboli C.F.A. (1977) Chief Financial Officer	48		$404,690

Monte Rosa Therapeutics
Latest News

Monday, 23 December 2024
08:50	Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term	zacks.com
Friday, 13 December 2024
07:00	Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors	globenewswire.com
Wednesday, 11 December 2024
07:00	Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders	globenewswire.com
07:00	Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer	globenewswire.com
Thursday, 5 December 2024
07:00	Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors	globenewswire.com
Monday, 2 December 2024
18:45	Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?	zacks.com
Tuesday, 26 November 2024
07:00	Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference	globenewswire.com
Friday, 15 November 2024
11:00	Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet	zacks.com
Thursday, 7 November 2024
09:35	Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
Wednesday, 6 November 2024
13:05	Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice	zacks.com
Wednesday, 30 October 2024
10:56	Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade	zacks.com
Monday, 28 October 2024
15:06	This Biotech Stock Has Doubled Its Value Today—Here's Why	investopedia.com
14:10	Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis	investors.com
07:00	Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders	globenewswire.com
Monday, 19 August 2024
07:00	Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study	globenewswire.com
Thursday, 8 August 2024
09:17	Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
07:00	Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Monday, 8 July 2024
08:36	Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day	globenewswire.com
Thursday, 27 June 2024
07:00	Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160	globenewswire.com
Friday, 14 June 2024
08:45	Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis	globenewswire.com
Thursday, 30 May 2024
07:00	Monte Rosa Therapeutics Announces Leadership Team Promotions	globenewswire.com
07:00	Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference	globenewswire.com
Tuesday, 21 May 2024
07:00	Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease	globenewswire.com
Thursday, 16 May 2024
07:00	Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering	globenewswire.com
Wednesday, 15 May 2024
16:01	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	globenewswire.com
Thursday, 9 May 2024
07:00	Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Thursday, 2 May 2024
16:01	Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer	globenewswire.com
Wednesday, 10 April 2024
09:51	Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why	Zacks Investment Research
Thursday, 4 April 2024
10:56	Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?	Zacks Investment Research
Friday, 22 March 2024
09:51	Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 31 Oct 2023

Monte Rosa Therapeutics: Roche Partnership Deal Could Bring Added Value

Frequently Asked Questions (FAQ)

What's the price of Monte Rosa Therapeutics stock today?

One share of Monte Rosa Therapeutics stock can currently be purchased for approximately $4.4.
When is Monte Rosa Therapeutics's next earnings date?

Unfortunately, Monte Rosa Therapeutics's (GLUE) next earnings date is currently unknown.
Does Monte Rosa Therapeutics pay dividends?

No, Monte Rosa Therapeutics does not pay dividends.
How much money does Monte Rosa Therapeutics make?

Monte Rosa Therapeutics has a market capitalization of 427.59M. Monte Rosa Therapeutics made a loss 135.35M US dollars in net income (profit) last year or -$0.53 on an earnings per share basis.
What is Monte Rosa Therapeutics's stock symbol?

Monte Rosa Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GLUE".
What is Monte Rosa Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Monte Rosa Therapeutics?

Shares of Monte Rosa Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Monte Rosa Therapeutics's key executives?
Monte Rosa Therapeutics's management team includes the following people:
- Dr. Markus Warmuth M.D. Pres, Chief Executive Officer & Director(age: 54, pay: $899,170)
- Mr. Ajim A. Tamboli C.F.A. Chief Financial Officer(age: 48, pay: $404,690)
How many employees does Monte Rosa Therapeutics have?

As Jul 2024, Monte Rosa Therapeutics employs 130 workers, which is 2% less then previous quarter.
When Monte Rosa Therapeutics went public?

Monte Rosa Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 24 Jun 2021.
What is Monte Rosa Therapeutics's official website?

The official website for Monte Rosa Therapeutics is monterosatx.com.
Where are Monte Rosa Therapeutics's headquarters?

Monte Rosa Therapeutics is headquartered at 645 Summer Street, Boston, MA.
How can i contact Monte Rosa Therapeutics?

Monte Rosa Therapeutics's mailing address is 645 Summer Street, Boston, MA and company can be reached via phone at +61 79492643.

Monte Rosa Therapeutics, Inc.

monterosatx.com

Exchange:

NASDAQ

Full time employees:

133

Industry:

Biotechnology

Sector:

Healthcare

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

+61 79492643

645 Summer Street
Boston, MA 02210

CIK: 0001826457
ISIN: US61225M1027
CUSIP: 61225M102